The “Covered Outpatient Drugs” final rule will save federal and state governments $2.7 billion over the course of five years, according to CMS. Finalizing the rule is one of CMS’ steps to ensure affordability and accessibility of prescription drugs.
The rule will not only guarantee Medicaid rebates correctly account for market prices, but also encourage pharmacies to use generic drugs by ensuring accurate cost reimbursement.
“This final rule makes changes that will save taxpayers billions and ultimately improve beneficiary access to prescription drugs,” said Vikki Wachino, CMS deputy administrator and director of the Center for Medicaid and CHIP services.
More articles on healthcare finance:
Andy Slavitt says CMS is working to recoup funds from ACA co-op failures
Kaiser Permanente CEO calls drug prices irrational
Pa. rural hospitals face threat due to state budget impasse: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
